Rivaroxaban gets EU support for use with acute coronary syndrome

The anticoagulant rivaroxaban should be considered for preventive use in patients with acute coronary syndrome, according to a recommendation from the EU's Committee for Medicinal Products for Human Use. The panel's opinion comes weeks after the FDA sought additional information instead of approving a similar indication in the U.S.

View Full Article in:

TheHeart.org (Montreal) (free registration) · Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX